FDA approves AZ's Farxiga in new heart failure prevention us...

The FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in adults with type 2 diabetes and other cardiovascular risks.<

AZ's Farxiga gets FDA Fast Track for heart failure

The FDA has fast-tracked AstraZeneca’s Farxiga (dapagliflozin) as a treatment to reduce risk of cardiovascular death, or worsening of heart failure, in adults with reduced or preserved ejec

Despite trial miss, Novartis still believes in Entresto for ...

AZ's Farxiga first in class to improve outcomes in heart fai...

AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabe

Novartis' heart failure drug misses expanded use trial targe...

Novartis has announced that its heart failure drug Entresto has failed in a trial that the company hoped would extend its use to a new group of patients with preserved ejection fraction.

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failu...